

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2291)

RE-DESIGNATION OF EXECUTIVE DIRECTOR TO NON-EXECUTIVE DIRECTOR AND CHANGE OF AUTHORIZED REPRESENTATIVE

RE-DESIGNATION OF EXECUTIVE DIRECTOR TO NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Ms. Zhang Yuxin (“**Ms. Zhang**”) has been re-designated from an executive Director to a non-executive Director (“**Ms. Zhang’s Re-designation**”), and ceased to act as the deputy general manager and the chief technology officer of the Company with effect from March 1, 2024.

Ms. Zhang joined the Group in May 2011 and has been a Director of the Company since January 29, 2021. For the biographical details of Ms. Zhang, please refer to the Company’s 2022 annual report dated April 25, 2023.

Save as disclosed herein, as at the date of this announcement, Ms. Zhang confirmed that (i) she has not held any directorship in other public listed companies in Hong Kong or overseas in the past three years; (ii) she does not hold any other position with the Company or subsidiaries of the Company; (iii) she does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) she does not have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Ms. Zhang will enter into a new service agreement with the Company regarding her appointment as non-executive Director for a term of three years. She will hold office until the next annual general meeting of the Company and be subject to the requirements for retirement by rotation and re-election pursuant to the articles of association of the Company. She is not entitled to any remuneration in connection with the performance of her duties under the appointment as a non-executive Director. She is entitled to the reimbursement of all reasonable out-of-pocket expenses properly and reasonably incurred in relation to the business of the Company or the discharge of her duties as director. The Company shall pay or provide to her such additional benefits as the Board shall in its absolute discretion deem appropriate.

Save as disclosed in this announcement, the Board is not aware of any other information relating to Ms. Zhang’s Re-designation that is required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and there is no other matters that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

Ms. Zhang confirmed that she has no disagreement with the Board and there is no other matter regarding Ms. Zhang's Re-designation that needs to be brought to the attention of the shareholders of the Company.

CHANGE OF AUTHORIZED REPRESENTATIVE

The Board hereby announces that Ms. Zhang has ceased to be an authorized representative of the Company due to Ms. Zhang's Re-designation as required under Rule 3.05 of the Listing Rules and Ms. Ko Mei Ying, a joint company secretary and the alternate authorized representative of the Company, has been appointed as an authorized representative of the Company as required under Rule 3.05 of the Listing Rules with effect from March 1, 2024.

APPOINTMENT OF HEAD OF RESEARCH AND DEVELOPMENT DEPARTMENTS

The Board also announces that the appointment of Mr. Qiu Kejin as the head of research and development department of the valve division of the Company and Mr. Hu Jinpeng as the head of research and development department of the occluder division of the Company, with effect from March 1, 2024, respectively.

The biographical details of Mr. Qiu Kejin and Mr. Hu Jinpeng are set out below:

Mr. Qiu Kejin, aged 36, joined the Group in June 2015. He was mainly engaged in the research and development of valve products in structural heart disease, and successively served as the research and development engineer, project manager and structural product manager. Mr. Qiu obtained a bachelor's degree in materials science and engineering from Harbin Engineering University in July 2009 and a doctoral degree in materials science from Harbin Engineering University in June 2015.

Mr. Hu Jinpeng, aged 32, joined the Group in July 2019 as the manager of the research and development department, responsible for various research and development of cardiac occluder products and management of the project team. Mr. Hu obtained a bachelor's degree in refrigeration and cryogenic technology from the University of Shanghai for Science and Technology in July 2009 and a master's degree in thermal energy and power engineering from the University of Shanghai for Science and Technology in May 2012.

By order of the Board

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*

樂普心泰醫療科技(上海)股份有限公司

Ms. Chen Juan

Chairman of the Board and Executive Director

Shanghai, the People's Republic of China

March 1, 2024

As at the date of this announcement, the Board comprises Ms. Chen Juan as the executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Liu Daozhi as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*

For identification purposes only.